Patent · US Active

Siglec-9 ECD fusion molecules

US11987612B2 · kind B2 · utility

0Cited by
1References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 3, 2020
Grant dateMay 21, 2024
Priority date—
Expiry dateJun 27, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.